Press room

Articles

Jan 2012	bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
Dec 2011	bioTheranostics’ Breast Cancer Index^SM shows clinical utility in late recurrence prognosis and identification of patients eligible for breast conserving surgery
Nov 2011	bioTheranostics’ CancerTYPE ID^® Linked with Improved Clinical Outcome and Longer Survival
July 2011	New Study Reports: CancerTYPE ID^® Expands Tumor Type Coverage and Demonstrates Clinical Utility
June 2011	Data from Clinical Studies of bioTheranostics’ CancerTYPE ID^® and Breast Cancer Index^SM Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
Dec 2010	bioTheranostics’ Breast Cancer Index^SM predicts risk for late recurrence in early stage ER-positive breast cancer patients

For information about bioTheranostics or to speak with a company representative, please contact:

Tim Schofield
bioTheranostics
(858) 587-5890 office
tim.schofield@biotheranostics.com